RO 317549

Drug Profile

RO 317549

Alternative Names: RO 318161

Latest Information Update: 14 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Antihyperlipidaemics; Antirheumatics; Indoles; Maleimides; Small molecules
  • Mechanism of Action Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Atherosclerosis; Cancer; Coronary artery restenosis; Rheumatic disorders

Most Recent Events

  • 12 Jul 1999 No-Development-Reported for Asthma in Switzerland (Unknown route)
  • 12 Jul 1999 No-Development-Reported for Atherosclerosis in United Kingdom (Unknown route)
  • 12 Jul 1999 No-Development-Reported for Coronary artery restenosis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top